These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy. Mura P; Faucci MT; Manderioli A; Bramanti G; Ceccarelli L J Pharm Biomed Anal; 1998 Oct; 18(1-2):151-63. PubMed ID: 9863953 [TBL] [Abstract][Full Text] [Related]
10. Compatibility of risedronate sodium tablets with food thickeners. Dansereau RJ; Crail DJ Am J Health Syst Pharm; 2008 Nov; 65(22):2133-6. PubMed ID: 18997142 [TBL] [Abstract][Full Text] [Related]
11. Effect of aging on the release of salbutamol sulfate from lipid matrices. San Vicente A; Hernández RM; Gascón AR; Calvo MB; Pedraz JL Int J Pharm; 2000 Nov; 208(1-2):13-21. PubMed ID: 11064207 [TBL] [Abstract][Full Text] [Related]
12. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting. Nasr M; Awad GA; Mansour S; Taha I; Al Shamy A; Mortada ND Eur J Pharm Biopharm; 2011 Nov; 79(3):601-11. PubMed ID: 21827854 [TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system. Gong T; Wang Z; Zhang Y; Sun C; Yang Q; Troczynski T; Häfeli UO J Biomed Mater Res A; 2014 Jul; 102(7):2295-304. PubMed ID: 23946228 [TBL] [Abstract][Full Text] [Related]
14. Hot melt extruded transdermal films based on amorphous solid dispersions in Eudragit RS PO: The inclusion of hydrophilic additives to develop moisture-activated release systems. Albarahmieh E; Qi S; Craig DQM Int J Pharm; 2016 Nov; 514(1):270-281. PubMed ID: 27863672 [TBL] [Abstract][Full Text] [Related]
15. Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats. Iwamoto J; Takeda T; Sato Y; Yeh JK Exp Anim; 2007 Apr; 56(2):103-10. PubMed ID: 17460355 [TBL] [Abstract][Full Text] [Related]
17. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Kwak HB; Kim JY; Kim KJ; Choi MK; Kim JJ; Kim KM; Shin YI; Lee MS; Kim HS; Kim JW; Chun CH; Cho HJ; Hong GY; Juhng SK; Yoon KH; Park BH; Bae JM; Han JK; Oh J Biol Pharm Bull; 2009 Jul; 32(7):1193-8. PubMed ID: 19571384 [TBL] [Abstract][Full Text] [Related]
18. Study on mechanism for amorphous drug stabilization using gelucire 50/13. Shimpi SL; Mahadik KR; Paradkar AR Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253 [TBL] [Abstract][Full Text] [Related]
19. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism. Namazi H J Crohns Colitis; 2012 Jul; 6(6):734. PubMed ID: 22483568 [No Abstract] [Full Text] [Related]
20. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]